STERIS plc (STE): Results of Operations and Financial Condition
STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ste6302026ex991.htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS incre
How this was made
The 30-second read
Why it matters
The key trading inputs are the combination of (1) Q1 operating and EPS beats versus prior year, (2) lower operating cash flow and free cash flow versus the prior-year quarter, (3) a $55M-$70M pre-tax restructuring charge range, and (4) updated capex to about $450M and free cash flow to about $800M while keeping full-year revenue growth and adjusted EPS guidance unchanged.
Market read
This is a primary earnings-and-guidance style disclosure with explicit cash flow, capex, and restructuring charge ranges, which can drive near-term repricing even with unchanged full-year EPS guidance.
What to watch
The restructuring completion is expected by fiscal 2030, so near-term earnings exclusion of charges may mask longer-term depreciation and labor impacts that could matter for subsequent quarters.
Background
STERIS filed an SEC 8-K with Exhibit 99.1 covering fiscal 2027 first-quarter results, a targeted restructuring tied to formulated chemistries consolidation, and updated capital expenditure and free cash flow expectations.
Ticker impact
STERIS reported fiscal 2027 Q1 results and reiterated guidance, while raising capex to about $450M tied to a new North Carolina formulated chemistries Center of Excellence.
Moderate volatility risk around the capex and restructuring details, with direction likely driven by how investors weigh unchanged EPS guidance versus lower Q1 cash flow and higher planned capex.
The filing provides fresh, decision-relevant datapoints: Q1 revenue/EPS, cash flow decline, restructuring charge range ($55M-$70M), and updated capex and free cash flow expectations. However, revenue and adjusted EPS guidance are unchanged, which can limit downside.
Market effects
Signals ongoing investment and restructuring in healthcare/life-sciences tools and consumables, potentially affecting peers’ sentiment around capex intensity and margin durability.
North Carolina facility buildout and closures in Missouri and Minnesota may shift regional industrial activity, but likely immaterial to broader markets.
Limited direct global read-through beyond healthcare infection prevention and sterilization supply chain demand stability.
Counterpoint
Investors may over-discount the cash flow decline because the company expects stronger full-year free cash flow offsetting higher capex, keeping the risk-reward closer to guidance than the headline capex number suggests.
Key entities
- companySTERIS plc
Reported fiscal 2027 first-quarter results, reiterated full-year guidance, and announced a restructuring and North Carolina Center of Excellence investment.
- executiveDan Carestio
CEO quoted on performance and unchanged revenue and earnings expectations.
